Population health and cost-effectiveness implications of a “treat all” recommendation for HCV: a review of the model-based evidence
LE Cipriano, JD Goldhaber-Fiebert - MDM policy & practice, 2018 - journals.sagepub.com
The World Health Organization HCV Guideline Development Group is considering a “treat
all” recommendation for persons infected with hepatitis C virus (HCV). We reviewed the …
all” recommendation for persons infected with hepatitis C virus (HCV). We reviewed the …
Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens
MH Eckman, JW Ward, KE Sherman - Clinical Gastroenterology and …, 2019 - Elsevier
Background & Aims Most persons infected with hepatitis C virus (HCV) in the United States
were born from 1945 through 1965; testing is recommended for this cohort. However, HCV …
were born from 1945 through 1965; testing is recommended for this cohort. However, HCV …
Epidemiology of hepatitis C virus infection in a country with universal access to direct‐acting antiviral agents: data for designing a cost‐effective elimination policy in …
J Crespo, A Cuadrado, C Perelló… - Journal of viral …, 2020 - Wiley Online Library
Accurate HCV prevalence estimates are necessary for guiding elimination policies. Our aim
was to determine the HCV prevalence and assess the cost‐effectiveness of a screen‐and …
was to determine the HCV prevalence and assess the cost‐effectiveness of a screen‐and …
Verification of decision-analytic models for health economic evaluations: an overview
EJ Dasbach, EH Elbasha - Pharmacoeconomics, 2017 - Springer
Decision-analytic models for cost-effectiveness analysis are developed in a variety of
software packages where the accuracy of the computer code is seldom verified. Although …
software packages where the accuracy of the computer code is seldom verified. Although …
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA‐C real‐world cohort
M Hernández‐Conde, I Fernández… - Journal of viral …, 2019 - Wiley Online Library
In randomized controlled trials of patients with chronic HCV infection, elbasvir/grazoprevir
(EBR/GZR) demonstrated high cure rates and a good safety profile. This study assessed the …
(EBR/GZR) demonstrated high cure rates and a good safety profile. This study assessed the …
Transplanting hepatitis C virus–infected versus uninfected kidneys into hepatitis C virus–infected recipients: a cost-effectiveness analysis
Background: Direct-acting antiviral agents are now available to treat chronic hepatitis C virus
(HCV) infection in patients with end-stage renal disease (ESRD). Objective: To examine …
(HCV) infection in patients with end-stage renal disease (ESRD). Objective: To examine …
[HTML][HTML] Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort
R Brandão, R Marcelino, F Gonçalves, I Diogo… - Viruses, 2018 - mdpi.com
This study is focused on the prevalent NS5 coding region resistance-associated
substitutions (RASs) in DAA-naive genotype (GT) 1 HCV-infected patients and their potential …
substitutions (RASs) in DAA-naive genotype (GT) 1 HCV-infected patients and their potential …
[HTML][HTML] Cost-utility of elbasvir/grazoprevir in patients with chronic hepatitis C genotype 1 infection
S Corman, EH Elbasha, SN Michalopoulos… - Value in Health, 2017 - Elsevier
Objective To evaluate the cost-utility of treatment with elbasvir/grazoprevir (EBR/GZR)
regimens compared with ledipasvir/sofosbuvir (LDV/SOF), ombitasvir/paritaprevir/ritonavir+ …
regimens compared with ledipasvir/sofosbuvir (LDV/SOF), ombitasvir/paritaprevir/ritonavir+ …
[HTML][HTML] Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong
Abstract Background Direct-acting antivirals (DAAs) are entering the hepatitis C virus (HCV)
treatment landscape in Hong Kong, prompting the need for cost–effectiveness evaluations of …
treatment landscape in Hong Kong, prompting the need for cost–effectiveness evaluations of …
Cost-Effectiveness of Elbasvir/Grazoprevir versus daclatasvir plus asunaprevir in patients with chronic hepatitis C virus genotype 1B infection in China
P Chen, A Ma, Q Liu - Clinical Drug Investigation, 2018 - Springer
Abstract Background and Objective New direct-acting antivirals (DAAs) have high efficacy
and tolerability in the treatment of hepatitis C virus (HCV) infection. The objective of this …
and tolerability in the treatment of hepatitis C virus (HCV) infection. The objective of this …